Analyst Ratings February 3, 2026

BMO Lifts DXC Technology Target to $17 but Keeps Neutral Rating

Price target raised amid mixed results: Q3 EPS and revenue beat but guidance and bookings signal ongoing instability

By Sofia Navarro DXC
BMO Lifts DXC Technology Target to $17 but Keeps Neutral Rating
DXC

BMO Capital has raised its price target on DXC Technology to $17 from $15 while retaining a Market Perform rating. The upgrade comes alongside a modest valuation argument from InvestingPro data, which shows a low P/E of 6.51 and suggests the stock may be undervalued versus Fair Value estimates. DXC reported stronger-than-expected Q3 2026 EPS and revenue, but the company trimmed its fiscal year revenue midpoint and disclosed a 17% year-over-year drop in bookings, prompting caution from the analyst.

Key Points

  • BMO Capital raised its DXC Technology price target to $17 from $15 but kept a Market Perform rating, indicating a neutral outlook.
  • DXC beat Q3 2026 EPS ($0.96 vs. $0.83 expected) and revenue ($3.19B vs. $3.18B expected), yet the stock dipped slightly in aftermarket trading.
  • Management lowered the fiscal year revenue midpoint and reported a 17% year-over-year decline in bookings, signaling weakness in short-term discretionary demand; implications affect the technology and IT services sectors and equity investors.

Price target change and rating

BMO Capital increased its price target for DXC Technology (NYSE:DXC) to $17.00 from $15.00, while leaving its coverage at a Market Perform rating. The new target implies only a small upside from the stock's current trading level of $14.61. InvestingPro data cited in the update shows DXC trading at a low price-to-earnings ratio of 6.51, and the stock is characterized as appearing undervalued when compared to available Fair Value estimates.


Quarterly results versus guidance

DXC reported third-quarter 2026 results that topped Wall Street expectations on the key metrics disclosed. The company posted earnings per share of $0.96, versus an expected $0.83, a surprise calculated at 15.66%. Quarterly revenue was $3.19 billion, narrowly exceeding the consensus estimate of $3.18 billion. Despite those upside surprises, the stock slipped modestly in aftermarket trading.

Alongside the results, management adjusted the fiscal year revenue outlook by lowering the midpoint of guidance. BMO highlighted disappointment in the firm's fourth-quarter revenue guidance, noting the guidance reduction as a point of concern.


Bookings and demand trends

The company reported a 17% year-over-year decline in bookings during the quarter. BMO characterized this decline as reflective of continued weakness in short-term discretionary work, underscoring demand pressures that can affect near-term revenue profiles.


Progress and ongoing challenges

While BMO acknowledged that DXC has shown progress on initiatives tied to artificial intelligence and go-to-market activity, the firm cautioned that management still faces a lengthy path to complete the company's turnaround and to achieve revenue stability. The analyst's decision to maintain a Market Perform rating signals a neutral stance despite the modest increase in the price target.


Market context and investor takeaway

The juxtaposition of an earnings beat and narrowed guidance, together with a sizable drop in bookings, presents a mixed picture for investors. On valuation metrics, the low P/E flagged by InvestingPro supports the view that the stock may be priced conservatively, yet operational headwinds and guidance revisions temper near-term optimism.

Risks

  • Lowered fiscal year revenue midpoint and disappointing fourth-quarter guidance - risk to company revenue and investor expectations in the technology and IT services sectors.
  • A 17% year-over-year decline in bookings driven by weaker short-term discretionary work - risk to near-term revenue growth and backlog stability.
  • Ongoing turnaround execution - BMO notes DXC still has a long way to go to reach revenue stability, representing operational and strategic execution risk.

More from Analyst Ratings

UBS Sticks With Neutral on Crocs as Market Sentiment Skews Bearish Feb 3, 2026 UBS Keeps Buy Rating on Coca-Cola Ahead of Q4 Results, Cites Durable Growth Path Feb 3, 2026 UBS Upholds Buy Rating on Walt Disney, Sets $138 Target as Analysts Largely Back the Stock Feb 3, 2026 UBS Sticks With Buy on Peloton, Sees Large Upside if Churn Holds Flat Feb 3, 2026 UBS Cuts Palantir Price Target to $180 as Analysts Parse Exceptional Growth Feb 3, 2026